Robert G. L. Shorr
Founder at Cornerstone Pharmaceuticals, Inc.
Active connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Sanjeev Luther | M | 62 |
Cornerstone Pharmaceuticals, Inc.
 Cornerstone Pharmaceuticals, Inc. Miscellaneous Commercial ServicesCommercial Services Rafael Pharmaceuticals, Inc. develops anti-cancer drug delivery technology. It produces highly selective and effective anti-cancer agents with minimal toxic effects on normal cells and tissues by attacking regulatory processes that are unique to cancer and not found in healthy cells. The firm would ensure a significant improvement in the safety profile of cancer treatment. The firm provides CPI-613, Altered Energy Metabolism Directed (AEMD) platform, targets enzymes that are involved in cancer cell energy metabolism and are located in the mitochondria of cancer cells. The company was founded by Robert G. L. Shorr and is headquartered in Cranbury, NJ. | 9 years |
| Uri Yablonka | M | 47 | 10 years | |
| Christofer Toumazou | M | 63 |
Imperial College London
| - |
| Raymond Kurzweil | M | 76 | 22 years | |
| Christopher Causey | M | 61 | 21 years | |
| Yael Gothelf | M | - | 17 years | |
| Rachel Janis Lomax | F | 78 |
Imperial College London
| 15 years |
| Alla Patlis | F | 37 | 12 years | |
| Chaim Lebovits | M | 53 | 17 years | |
| Robert J. Frey | M | 70 |
Stony Brook University
| - |
| Raymond Dwek | M | 82 | 22 years | |
| Christopher Patusky | M | 60 | 22 years | |
| Howard Jonas | M | 68 |
Cornerstone Pharmaceuticals, Inc.
Cornerstone Pharmaceuticals, Inc. Miscellaneous Commercial ServicesCommercial Services Rafael Pharmaceuticals, Inc. develops anti-cancer drug delivery technology. It produces highly selective and effective anti-cancer agents with minimal toxic effects on normal cells and tissues by attacking regulatory processes that are unique to cancer and not found in healthy cells. The firm would ensure a significant improvement in the safety profile of cancer treatment. The firm provides CPI-613, Altered Energy Metabolism Directed (AEMD) platform, targets enzymes that are involved in cancer cell energy metabolism and are located in the mitochondria of cancer cells. The company was founded by Robert G. L. Shorr and is headquartered in Cranbury, NJ. | 11 years |
| Louis Sullivan | M | 90 | 22 years | |
| Szilard Voros | M | - |
Stony Brook University
| - |
| Mark C. Enright | M | - |
Imperial College London
| 17 years |
| Yong Sun Mah | M | 62 |
Imperial College London
| 13 years |
| Elaine Holmes | M | - |
Imperial College London
| - |
| Dame Alison Nimmo | F | - |
Imperial College London
| - |
| Claudio Albanese | M | 61 |
Imperial College London
| 20 years |
| Charlotte Katherine Williams | F | - |
Imperial College London
| - |
| Andy McKeon | M | 68 |
Imperial College London
| - |
| Shawn Heilbron | M | - |
Stony Brook University
| - |
| Bill Cleary | M | - |
Stony Brook University
| - |
| Patrick Wilmerding | M | - |
Cornerstone Pharmaceuticals, Inc.
Cornerstone Pharmaceuticals, Inc. Miscellaneous Commercial ServicesCommercial Services Rafael Pharmaceuticals, Inc. develops anti-cancer drug delivery technology. It produces highly selective and effective anti-cancer agents with minimal toxic effects on normal cells and tissues by attacking regulatory processes that are unique to cancer and not found in healthy cells. The firm would ensure a significant improvement in the safety profile of cancer treatment. The firm provides CPI-613, Altered Energy Metabolism Directed (AEMD) platform, targets enzymes that are involved in cancer cell energy metabolism and are located in the mitochondria of cancer cells. The company was founded by Robert G. L. Shorr and is headquartered in Cranbury, NJ. | - |
| Judy Murrah | F | 66 |
Stony Brook University
| - |
| Michael Gouzman | M | - |
Stony Brook University
| - |
| Hugh Brady | M | 64 |
Imperial College London
| 2 years |
| Eric Cutsem | M | - |
Cornerstone Pharmaceuticals, Inc.
Cornerstone Pharmaceuticals, Inc. Miscellaneous Commercial ServicesCommercial Services Rafael Pharmaceuticals, Inc. develops anti-cancer drug delivery technology. It produces highly selective and effective anti-cancer agents with minimal toxic effects on normal cells and tissues by attacking regulatory processes that are unique to cancer and not found in healthy cells. The firm would ensure a significant improvement in the safety profile of cancer treatment. The firm provides CPI-613, Altered Energy Metabolism Directed (AEMD) platform, targets enzymes that are involved in cancer cell energy metabolism and are located in the mitochondria of cancer cells. The company was founded by Robert G. L. Shorr and is headquartered in Cranbury, NJ. | - |
| Richard Erskine Frere Leakey | M | 79 |
Stony Brook University
| - |
| Marsha Pollard | F | - |
Stony Brook University
| - |
| Hans Schellnhuber | M | - |
Imperial College London
| - |
| Samuel L. Stanley | M | - |
Stony Brook University
| 15 years |
| Aaron Drillick | M | - |
Cornerstone Pharmaceuticals, Inc.
Cornerstone Pharmaceuticals, Inc. Miscellaneous Commercial ServicesCommercial Services Rafael Pharmaceuticals, Inc. develops anti-cancer drug delivery technology. It produces highly selective and effective anti-cancer agents with minimal toxic effects on normal cells and tissues by attacking regulatory processes that are unique to cancer and not found in healthy cells. The firm would ensure a significant improvement in the safety profile of cancer treatment. The firm provides CPI-613, Altered Energy Metabolism Directed (AEMD) platform, targets enzymes that are involved in cancer cell energy metabolism and are located in the mitochondria of cancer cells. The company was founded by Robert G. L. Shorr and is headquartered in Cranbury, NJ. | - |
| A Joseph Stern | M | - |
Cornerstone Pharmaceuticals, Inc.
Cornerstone Pharmaceuticals, Inc. Miscellaneous Commercial ServicesCommercial Services Rafael Pharmaceuticals, Inc. develops anti-cancer drug delivery technology. It produces highly selective and effective anti-cancer agents with minimal toxic effects on normal cells and tissues by attacking regulatory processes that are unique to cancer and not found in healthy cells. The firm would ensure a significant improvement in the safety profile of cancer treatment. The firm provides CPI-613, Altered Energy Metabolism Directed (AEMD) platform, targets enzymes that are involved in cancer cell energy metabolism and are located in the mitochondria of cancer cells. The company was founded by Robert G. L. Shorr and is headquartered in Cranbury, NJ. | - |
| Hettiaratchy Peter Shehan | M | 55 |
Imperial College London
| - |
| Chi Van Dang | M | - |
Cornerstone Pharmaceuticals, Inc.
Cornerstone Pharmaceuticals, Inc. Miscellaneous Commercial ServicesCommercial Services Rafael Pharmaceuticals, Inc. develops anti-cancer drug delivery technology. It produces highly selective and effective anti-cancer agents with minimal toxic effects on normal cells and tissues by attacking regulatory processes that are unique to cancer and not found in healthy cells. The firm would ensure a significant improvement in the safety profile of cancer treatment. The firm provides CPI-613, Altered Energy Metabolism Directed (AEMD) platform, targets enzymes that are involved in cancer cell energy metabolism and are located in the mitochondria of cancer cells. The company was founded by Robert G. L. Shorr and is headquartered in Cranbury, NJ. | - |
| John Lee Allen | M | - |
Imperial College London
| 4 years |
| Craig Moskowitz | M | - |
Cornerstone Pharmaceuticals, Inc.
Cornerstone Pharmaceuticals, Inc. Miscellaneous Commercial ServicesCommercial Services Rafael Pharmaceuticals, Inc. develops anti-cancer drug delivery technology. It produces highly selective and effective anti-cancer agents with minimal toxic effects on normal cells and tissues by attacking regulatory processes that are unique to cancer and not found in healthy cells. The firm would ensure a significant improvement in the safety profile of cancer treatment. The firm provides CPI-613, Altered Energy Metabolism Directed (AEMD) platform, targets enzymes that are involved in cancer cell energy metabolism and are located in the mitochondria of cancer cells. The company was founded by Robert G. L. Shorr and is headquartered in Cranbury, NJ. | - |
| Manuel London | M | - |
Stony Brook University
| - |
| Lord Darzi | M | 63 |
Imperial College London
| 19 years |
| Christopher Levy | M | - |
Stony Brook University
| - |
| Abderrazzak Merzouki | M | 60 |
Imperial College London
| 17 years |
| Andrew Crofton Sleigh | M | 74 |
Imperial College London
| - |
| Katherine Heaviside | F | 79 |
Stony Brook University
| - |
| Sidney Braginsky | M | 86 |
Stony Brook University
| - |
| John Allan | M | 75 |
Imperial College London
| 4 years |
| Toby Courtauld | M | 56 |
Imperial College London
| - |
| Yair Tauman | M | 65 |
Stony Brook University
| - |
| Rohinton Kalifa | M | 62 |
Imperial College London
| - |
| Alexander P. Hatsis | M | 73 |
Stony Brook University
| - |
| David King | M | 65 |
Stony Brook University
| - |
| Paul Bingham | M | - |
Cornerstone Pharmaceuticals, Inc.
Cornerstone Pharmaceuticals, Inc. Miscellaneous Commercial ServicesCommercial Services Rafael Pharmaceuticals, Inc. develops anti-cancer drug delivery technology. It produces highly selective and effective anti-cancer agents with minimal toxic effects on normal cells and tissues by attacking regulatory processes that are unique to cancer and not found in healthy cells. The firm would ensure a significant improvement in the safety profile of cancer treatment. The firm provides CPI-613, Altered Energy Metabolism Directed (AEMD) platform, targets enzymes that are involved in cancer cell energy metabolism and are located in the mitochondria of cancer cells. The company was founded by Robert G. L. Shorr and is headquartered in Cranbury, NJ. | - |
| Yi Ke Guo | M | 61 |
Imperial College London
| 22 years |
| Sanford Simon | M | 81 |
Stony Brook University
| 55 years |
| Jeffrey S. Yablon | M | - |
Stony Brook University
| - |
| Alice Gast | M | 65 |
Imperial College London
| 10 years |
| I. V. Ramakrishnan | M | - |
Stony Brook University
| - |
| Daniel R. Ferrara | M | - |
Stony Brook University
| - |
| Sara Murray | F | 56 |
Imperial College London
| - |
| David Shrier | M | 49 |
Imperial College London
| 4 years |
| William L. Heaton | M | - |
Stony Brook University
| - |
| Eric Morgan Yeatman | M | 61 |
Imperial College London
| 35 years |
| Edward Bergman | M | - |
Stony Brook University
| - |
| Benjamin Chu | M | - |
Stony Brook University
| - |
| Benjamin S. Hsiao | M | - |
Stony Brook University
| - |
| Zuzana Zachar | M | - |
Cornerstone Pharmaceuticals, Inc.
Cornerstone Pharmaceuticals, Inc. Miscellaneous Commercial ServicesCommercial Services Rafael Pharmaceuticals, Inc. develops anti-cancer drug delivery technology. It produces highly selective and effective anti-cancer agents with minimal toxic effects on normal cells and tissues by attacking regulatory processes that are unique to cancer and not found in healthy cells. The firm would ensure a significant improvement in the safety profile of cancer treatment. The firm provides CPI-613, Altered Energy Metabolism Directed (AEMD) platform, targets enzymes that are involved in cancer cell energy metabolism and are located in the mitochondria of cancer cells. The company was founded by Robert G. L. Shorr and is headquartered in Cranbury, NJ. | - |
| Patrick E. Maloney | M | 68 |
Stony Brook University
| - |
| Clive Zickel | M | - |
Stony Brook University
| - |
| Yacov Shamash | M | 74 |
Stony Brook University
| 23 years |
| Robert Dickinson | M | - |
Imperial College London
| - |
| Michael A. Bender | M | - |
Stony Brook University
| - |
| Shmuel Levinger | M | - |
Cornerstone Pharmaceuticals, Inc.
Cornerstone Pharmaceuticals, Inc. Miscellaneous Commercial ServicesCommercial Services Rafael Pharmaceuticals, Inc. develops anti-cancer drug delivery technology. It produces highly selective and effective anti-cancer agents with minimal toxic effects on normal cells and tissues by attacking regulatory processes that are unique to cancer and not found in healthy cells. The firm would ensure a significant improvement in the safety profile of cancer treatment. The firm provides CPI-613, Altered Energy Metabolism Directed (AEMD) platform, targets enzymes that are involved in cancer cell energy metabolism and are located in the mitochondria of cancer cells. The company was founded by Robert G. L. Shorr and is headquartered in Cranbury, NJ. | 2 years |
Connections Chart
Multi-company connection
Former connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Yoram Drucker | M | 59 | 3 years | |
| Adrian Harel | M | 67 | 2 years | |
| John Maxim Ferrari | M | 69 | 14 years | |
| Ralph Kern | M | 67 | 6 years | |
| Arturo O. Araya | M | 53 | 4 years | |
| Michael Kyriakides | M | - |
Imperial College London
| 7 years |
| Abraham Efrati | M | 74 | 4 years | |
| Abraham Israeli | M | 70 | 4 years | |
| Fumi Kato | M | - |
Stony Brook University
| 8 years |
| Jo Criddle | F | - |
Imperial College London
| 4 years |
| Deji Sasegbon | M | - |
Imperial College London
| 9 years |
| Philippa Christoforou | M | - |
Imperial College London
| 4 years |
| Clea Kolster | F | - |
Imperial College London
| 8 years |
| Aiste Satkute | F | - |
Imperial College London
| 1 years |
| Guan Hua Liu | M | 41 |
Imperial College London
| 4 years |
| Ram Rasaratnam | M | - |
Imperial College London
| 5 years |
| Joshua Lowe | M | - |
Imperial College London
| 4 years |
| Tracy Rice | F | - |
Stony Brook University
| 6 years |
| Adam Karlsson | M | - |
Imperial College London
| 6 years |
| Claire Vassie | F | - |
Imperial College London
| 6 years |
| Martin Knight | M | 74 |
Imperial College London
| 18 years |
| Xu Dong Ren | M | 40 |
Imperial College London
| 5 years |
| Elisa Petris | M | 45 |
Imperial College London
| 7 years |
| Hemali Nisansala Hemachandra | F | - |
Imperial College London
| 5 years |
| Edward Harper | M | - |
Imperial College London
| 2 years |
| Ruchir Saraswat | M | - |
Imperial College London
| 10 years |
Statistics
| Country | Connections | % of total |
|---|---|---|
| United States | 57 | 57.58% |
| United Kingdom | 42 | 42.42% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Robert G. L. Shorr
- Personal Network
